« The Evidence and Clinical Rationale for the Use of JAK Inhibitors in the Management of AD  », Can Allergy Immunol Today, vol. 2, nᵒ s11, p. 3–11, nov. 2022, doi: 10.58931/cait.2022.2s1148.